# CARES-005 (NCT04559607)

> TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

No report yet. It can be ordered.

- Drugs tested: camrelizumab plus rivoceranib
- Indication: unresectable hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04559607
- Phase: NA
- Status: UNKNOWN
- Sponsor: Zhongda Hospital
- Conditions: Hepatocellular Carcinoma
- Interventions: Camrelizumab; TACE; Apatinib
- Enrollment: 188
- Primary outcome: Progression-free survival (PFS) by investigator

## Indexed commentary on CARES-005 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cares-005-nct04559607

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04559607", "email": "<work email>"}; the inbox owner confirms by the emailed link.